Objectives: The objective of this study was to evaluate the correlation between dynamic gadoxetic acidYenhanced magnetic resonance imaging parameters and specific uptake values (SUVs) derived from 18 fluorodeoxyglucose ( 18 F-FDG) and 68 Ga-DOTA-Tyr(3)-octreotate ( 68 Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in patients with liver metastases of neuroendocrine neoplasms. Methods: A total of 42 patients with hepatic metastases of neuroendocrine neoplasms were prospectively enrolled and underwent both dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) and PET/CT, using either 18 F-FDG or 68 Ga-DOTATATE as tracer. The DCE-MRI was performed at 3 T with gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid acquiring 48 slices every 2.2 seconds for 5 minutes. Three regions of interest (ROIs) representing the liver background and up to 3 ROIs representing metastatic liver tissue were coregistered in the PET/CT and in the DCE-MRI data sets. For each patient, a dedicated dual-inlet, 2-compartment uptake model was fitted to the enhancement curves of DCE-MRI ROIs and perfusion parameters were calculated. Lesion-to-background ratios of SUVs were correlated with corresponding lesion-to-background ratios of the perfusion parameters arterial plasma flow, venous plasma flow, total plasma flow, extracellular mean transit time, extracellular volume, arterial flow fraction, intracellular uptake rate, and hepatic uptake fraction using the Spearman coefficient. Results: Whereas the lesion-to-background ratios of arterial plasma flow and arterial flow fraction of liver metastases correlated negatively with the lesion-to-background ratios of SUV mean derived from 68 Ga-DOTATATE PET/ CT (r = j0.54, P G 0.001; r = j0.39, P G 0.001, respectively), they correlated positively with the lesion-to-background ratios of SUV mean derived from 18 F-FDG-PET/CT (r = 0.51, P G 0.05; r = 0.68, P G 0.01, respectively). The lesion-to-background ratios of the DCE-MRI parameters extracellular mean transit time and extracellular volume correlated very weakly with the lesionto-background ratios of SUV mean from 68 Ga-DOTATATE PET/CT, whereas venous plasma flow, total plasma flow, hepatic uptake fraction, and intracellular uptake rate showed no correlation between DCE-MRI and PET/CT. Conclusions: Both A ccording to the current World Health Organization classification 2010, neuroendocrine neoplasms (NENs) of the gastroenteropancreatic system are classified into well-differentiated neuroendocrine tumors and poorly differentiated, high-grade malignant neuroendocrine carcinomas.
A ccording to the current World Health Organization classification 2010, neuroendocrine neoplasms (NENs) of the gastroenteropancreatic system are classified into well-differentiated neuroendocrine tumors and poorly differentiated, high-grade malignant neuroendocrine carcinomas. 1 Neuroendocrine neoplasms of the gastroenteropancreatic system often present with liver metastases already at the time point of initial diagnosis. 2 The stage of metastatic disease is associated with a high morbidity and mortality. In a major database with 35,618 cases of NEN, the 5-year survival of patients with well-to moderately differentiated neoplasms decreased from approximately 82% to 35% with the presence of distant metastases and from 38% to 4% for poorly differentiated neoplasms. 3 Therefore, accurate staging of patients experiencing NEN has substantial prognostic impact with consequences for further management and therapeutic strategies.
Imaging modalities for hepatic metastases of NENs include contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) with various radiotracers. For NEN liver metastases, characteristic magnetic resonance imaging features have been described 4 including markedly hyperintense signal intensity on T2-weighted images and hypervascularity in the arterial phase after contrast agent administration. 5, 6 Whereas existing diagnostic imaging methods of contrast-enhanced MRI or CT provide limited evaluation of tissue characteristics beyond morphology, PET examinations provide additional physiological information, depending on the radiotracer. Whereas 18 fluorodeoxyglucose ( 18 F-FDG) is primarily used to visualize metabolic activity in poorly differentiated NENs with high proliferation indices, 68 Ga-DOTA-Tyr(3)-octreotate ( 68 Ga-DOTATATE) is a somatostatin analog that binds to somatostatin receptors and is especially suited for well-differentiated tumors. 7 A recent study suggests that the use of 68 Ga-DOTATATE PET/CT may increase detection sensitivity compared with contrastenhanced MRI or CT. 8 Dynamic contrast-enhanced MRI (DCE-MRI) of the liver is capable of detecting perfusion parameters and quantifying the microcirculatory states of the liver parenchyma and of liver lesions.
9Y11
Thus, perfusion imaging of the liver can potentially improve the shortcomings of contrast-enhanced MRI and go beyond purely morphologic imaging by providing regional and global information about blood flow and function within the liver. 12 Some articles report the value of gadoxetic acidYenhanced DCE-MRI in focal and diffuse
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13Y17 However, we have found no reports that correlate specific uptake values (SUVs) of PET/CT and DCE-MRI parameters.
Given the recent development of hybrid MRI techniques, particularly MRI/PET, we see a need to investigate the relationship of functional and metabolic data derived from these 2 different modalities. Early studies examining the potential of MRI/PET report the potential to acquire morphologic, functional, and metabolic information in 1 examination. 18 Young patients with metastatic disease who receive sequential follow-up examinations might especially benefit from this new hybrid technique because the total radiation dose is significantly decreased in MRI/PET compared with PET/ CT. 19 A recent study investigated SUV derived from MRI/PET and PET/CT in patients experiencing NEN and reported strong correlations. 20 Whereas the MRI component provided mainly morphologic information, the combination of MRI/PET with perfusion imaging showed potential to add new functional information. 21 Therefore, the aim of the current study was to analyze the association between gadoxetic acidYenhanced DCE-MRI parameters using a dual-inlet, 2-compartment uptake model and SUVs derived from PET/CT, using 18 F-FDG and 68 Ga-DOTATATE in patients with known liver metastases from NEN.
METHODS

Patient Cohort
Between May 2009 and December 2011, we prospectively examined 42 patients with known hepatic metastases of NEN of various primary tumor sites, both in DCE-MRI and in PET/CT. The local institutional review board approved the study, and informed consent to the study and the DCE-MRI was obtained from all patients before the examinations. The diagnosis of NEN was confirmed histopathologically in all patients. If the origin of the primary tumor site was known, histological diagnosis was provided through resection or biopsy of the primary tumor. For the patients with disease of unknown origin, tissue was obtained through biopsy of liver metastases. Furthermore, in those patients who received the resection or biopsy in our tertiary center, we also obtained Ki-67 labeling index to assess tumor grading.
Data Acquisition
All MRI examinations (59/42 patients) were scheduled as regular follow-up imaging surveillance that are routinely performed every 3 months in our tertiary center for NENs to assess the exact tumor burden of the liver. Furthermore, for assessment of other distant metastases, all patients underwent whole-body PET/CT imaging as part of their routine follow-up imaging, using either 18 F-FDG or 68 Ga-DOTATATE. Somatostatin analog therapy was not stopped for PET/CT examinations. There was no interval regarding previous treatments. In most cases, DCE-MRI and PET/CT data sets were acquired within 24 hours (81%). All examinations were separated by less than 14 days. Age and sex were recorded for all patients. Furthermore, the primary tumor site of the NEN, the time since the first diagnosis of NEN, and the number of previous therapies were obtained from the patients' records. The patients' hematocrit levels were recorded on the day of the DCE-MRI examination. Overall, 12 patients had more than 1 follow-up examination; those examinations were included in the analysis, and statistical correction for repeated measurements was performed as described in the succeeding paragraphs.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed with a 3.0-T magnet (MAGNETOM Verio; Siemens Healthcare, Erlangen, Germany) by using a 32-channel phased-array body and spine coil. We used an MRI protocol consisting of precontrast sequences including in-and opposed-phased T1-weighted (T1w) images, postcontrast sequences including T2-weighted imaging, as well as coronal and transverse T1w 3-dimensional (3D) gradient-recalled echo (GRE) images with fat saturation 20 minutes after the contrast injection.
In addition, DCE-MRI data were acquired using a 3D T1w spoiled gradient-echo sequence that was accelerated using view sharing and parallel imaging (time-resolved angiography with stochastic trajectories). Imaging parameters were as follows: repetition time (TR)/echo time (TE), 2. As contrast agent, 0.1 mL/kg of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) (Primovist; Bayer Healthcare, Germany) was injected via the antecubital vein with a flow of 2 mL/s 10 seconds after starting the acquisition and flushed with 30 mL saline at the same rate. The patients were instructed to breathe shallowly during the acquisition.
Positron Emission Tomography/Computed Tomography
All PET/CT examinations were part of the clinical routine follow-up imaging protocol of patients with NEN. The patients were examined with either 68 Ga-DOTATATE or 18 F-FDG, depending on the tumor grading and the tracer used in previous PET/CT examinations as described in the following section: If the examination was the first PET/CT examination of a patient, 68 Ga-DOTATATE was used in tumors with low (G1; Ki67 e2%), intermediate (G2; 2% G Ki67 G 20%), or unknown proliferation indices, 22 whereas 18 F-FDG was used in tumors with high proliferation (G3; Ki67 Q 20%) indices. 23, 24 In case that a patient received previous examinations, the previously used tracer was retained to provide for better follow-up interpretation. 68 Ga-DOTATATE was prepared as described earlier. 25, 26 Whole-body PET scans were acquired in 3D mode with 3 minutes per bed position using a Biograph 64 TruePoint PET/CT scanner (Siemens Healthcare, Erlangen, Germany). F-labeled glucose tracers. 28, 29 Emission data were reconstructed with attenuation correction on the basis of low-dose CT (20 mA; 140 kV; matrix, 512 Â 512). All imaging procedures were performed in combination with a diagnostic CT scan (100Y190 mA s, depending on the region of the scanned organ; 120 kV; collimation, 2.5 mm; pitch, 1.5) of the head, the thorax, the abdomen, and the pelvis performed after a 2.5 mL/s intravenous injection of an iodinated contrast agent (Iomeprol 350 mg/mL; Bracco SpA, Milan, Italy; 1.5 mL/kg body weight). The scan was begun 50 seconds after the contrast injection to depict the portal-venous phase of enhancement.
Postprocessing
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in IDL6.4 (ITT, Boulder, CO). 11, 30, 31 Contrast agent concentrations were approximated by the relative signal enhancement. 32 Arterial and venous blood concentrations were converted to plasma concentrations using the patients' hematocrit.
First semiquantitative maps including maximum signal intensity enhancement, time-to-peak, and area under the curve were calculated by subsuming the information from all acquired data sets for each slice. The arterial input function was defined inside the lumen of the abdominal aorta on a maximum enhancement map. Therefore, a radiologist with 5 years' experience in abdominal imaging and DCE-MRI broadly circumscribed the aorta above the renal arteries by drawing a region of interest (ROI) on 3 or 4 adjacent slices. To select only the voxels clearly within the aorta, this ROI was shrunk automatically by extracting the pixels in the top 10% of the value range. Quantitative maps including plasma flow, volume of distribution, and mean transit time were calculated by deconvolving tissue concentrations with the arterial input function. 31, 33, 34 The venous input function was then defined on a plasma flow map by drawing a ROI around both intrahepatic and extrahepatic portions of the portal vein on 3 or 4 adjacent slices. This ROI was also shrunk by selecting the pixels in the top 10% of the value range. 11 The complete 4-parameter dual-inlet, 2-compartment uptake model, with arterial delay correction, was fitted to all defined ROIs representing metastatic or background liver tissue (provided in the succeeding paragraphs). This model was used because it takes the special pharmacokinetic properties of the hepatobiliary contrast agent Gd-EOB-DTPA into account and has been recently validated for this purpose by Sourbron et al. 11 The following perfusion parameters were calculated: arterial plasma flow (APF), venous plasma flow (VPF), total plasma flow (TPF), extracellular mean transit time (exMTT), extracellular volume (exVol), arterial flow fraction (AFF), intracellular uptake rate (UR), and hepatic uptake fraction (UF).
Definition of ROIs in PET/CT and DCE-MRI Data Sets
For each patient, 3 regions representing liver background tissue and up to 3 viable metastases with diameters greater than 20 mm were identified on coronal PET/CT data sets and DCE-MRI semiparametric maps. To confirm whether identified lesions correspond to metastases rather than to the liver background, information from delayed coronal T1w GRE sequences 20 minutes after the contrast injection of Gd-EOB-DTPA, diffusion-weighted imaging, contrastenhanced T1w sequences, and T2-weighted sequences were taken into account. The ROIs representing the liver background were drawn as circles with diameters of 15 to 20 voxels. The ROIs representing the metastases included the entire lesion with the exception of central nonenhancing areas that likely represented central necrosis.
The DCE-MRI and PET/CT data sets were coregistered using anatomic landmarks and distances from the ROI to the landmarks, standardized as follows: the origin of the renal arteries was defined in PET/CT and DCE-MRI mean transit time semiparametric maps. The ROIs were manually first defined in the PET/CT data sets. Corresponding distances in x, y, and z planes from the anatomic landmarks were calculated using Digital Imaging and Communications in Medicine (DICOM)-header information (slice thickness and slice margin). The DCE-MRI ROIs were then defined according to the PET/CT ROIs, the calculated distances from the anatomic landmarks, and the morphologic information from T1 sequences obtained 20 minutes after the contrast medium injection.
Normalization of SUV and DCE-MRI parameters of metastases to liver background
To diminish the influence of examination-based data, we calculated the relative tracer uptake of metastases by dividing the SUV of metastases by the mean SUV of 3 ROIs representing normal-appearing liver tissue (lesion-to-background ratio). 35, 36 This was performed accordingly for all DCE-MRI parameters.
Statistical Analysis
Statistical analyses were performed using commercially available software (SAS 9.3; SAS Institute Inc, Cary, NC). To confirm whether continuous variables were normally distributed, the Kolmogorov-Smirnov test was applied for SUV, APF, VPF, TPF, exVol, exMTT, AFF, UF, and UR. Variables following normal distribution are reported as mean (SD). To examine whether normally distributed variables were different between the metastases and the liver background, the Student t test for independent samples was applied to test for differences in means. In case of nonnormal distribution, the Wilcoxon rank sum test was used.
Dynamic contrast-enhanced magnetic resonance imaging perfusion parameters of metastases were normalized to liver background and correlated to the corresponding relative SUV mean using the Spearman coefficient with Fisher z-transformation. These analyses were calculated separately for examinations using 18 F-FDG or 68 Ga-DOTATATE. The SUV mean was used instead of SUV max to facilitate a comparison between the PET/CT and DCE-MRI parameters because the DCE-MRI parameters were based on mean values. A generalized estimating equation (GEE) model cluster analysis was then performed to estimate the statistical effect of multiple measurements within the same data set (multiple lesions per examination and multiple examinations per patient).
RESULTS
Patient Characteristics
The mean (SD) age of the study population was 59.8 (9.9). The primary tumor sites of the NEN were pancreas (n = 10), ileum (n = 9), jejunum (n = 7), colon (n = 6), stomach (n = 4), and lung (n = 1). Tumor origin was unknown in 5 patients. Many patients had received histopathological evaluation in other hospitals. Therefore, the Ki-67 index was not determined in all patients. Most of the patients had multiple previous treatments: transarterial radioembolization using 90 yttrium (n = 27), somatostatin analog therapy with ocreotide or lanreotide (n = 17), peptide receptor radionuclide therapy using 177 lutetium-DOTA-TATE and 90 yttrium-DOTA-TATE (n = 16), chemotherapy (n = 12), hemihepatectomy (n = 8), transarterial chemoembolization (n = 5), or radiofrequency ablation (n = 1) ( Table 1) .
Of 59 DCE-MRI examinations, 17 were excluded from the analysis because no lesions with diameters greater than 20 mm could be defined on either PET/CT or DCE-MRI images (n = 5), the venous input function could not be clearly identified (n = 3), acquisition was incorrect because of strong motion artifacts (n = 6), or delayed start of DCE-MRI sequence (n = 3). Among the 42 remaining examinations, there were 31 examinations with 68 Ga-DOTATATE-PET as tracer and 11 examinations with 18 F-FDG-PET as tracer (Fig. 1) . A total of 92 ROIs could be defined in the metastases and a total of 126 ROIs could be defined in the normal-appearing liver tissue on both DCE-MRI and PET/CT images. Figure 2 shows the appearance of the metastases and the liver background in DCE-MRI, PET/CT, and T1w 3D GRE sequences.
Differentiation Between the Metastases and the Liver Background
The following parameters exhibited significantly different values for the metastatic tissue compared with liver background: SUV mean derived from 68 Ga-DOTATATE PET/CT and from 
Positron Emission Tomography/Computed Tomography Findings
The SUV mean (SD) from 68 Ga-DOTATATE PET/CT was significantly higher for the metastases (17.09 [8.99] ; n = 72) than for the liver background (4.78 [1.52]) (P G 0.001). The SUV mean (SD) from 18 F-FDG PET/CT was also higher for the liver metastases (9.79 [5.31] ; n = 20) than for the ROIs representing normal liver tissue (2.25T0.71) (P G 0.001).
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Findings
The metastases showed a significantly higher APF (65.11 [55.82] mL/min per 100 mL; n = 92) compared with the normal liver tissue (19.16 [17. 59] mL/min per 100 mL) (P G 0.001), whereas the VPF rates were significantly lower for the metastases (10.30 [27. 77] mL/min per 100 mL; n = 92) than for the liver background (33.80 [31. 53] mL/min per 100 mL) (P G 0.001). The total plasma flow (APF + VPF) was increased up to 42% in the metastases (75. 41 [10.35] seconds) (P = 0.236).
The UR of Gd-EOB-DTPA was significantly different between the metastases and the liver background (P G 0.001) and was significantly lower for the metastases (2.02 [3.27] per 100 mL/min; n = 92) than for the normal liver tissue ROIs (3.37 [2. 05] per 100 mL/min).
The UF of Gd-EOB-DTPA, too, was significantly lower for the metastases (2.81% [2.33%]; n = 92) than for the liver background (7.67% [5.53%]) (P G 0.001).
Correlation Analysis of Lesion-to-Background Ratios of Metastases in SUV From the PET/CT and DCE-MRI Parameters 68 Ga-DOTA-Tyr(3)-octreotate Table 2 shows the results of correlations between SUV mean derived from 68 Ga-DOTATATE PET/CT and DCE-MRI parameters: whereas the lesion-to-background ratios of SUV mean correlated significantly negative to the lesion-to-background ratios of APF values (r = j0.54; P G 0.001; 95% confidence interval [CI], j0.69 to The mean (SD) age was 59.8 (9.9) y (age range, 42Y80 y). PRRT indicates peptide receptor radionuclide therapy; RFA, radiofrequency ablation; TARE, transarterial radioembolization; TACE, transarterial chemoebolization. j0.36) and of AFF (r = j0.39; P G 0.001; 95% CI, j0.57 to j0.17) (Fig. 3) , the lesion-to-background ratios of SUV mean showed a significant positive correlation to relative exMTT (r = 0.29; P = 0.012; 95% CI, 0.07Y0.49) and to exVol (r = 0.27; P = 0.024; 95% CI, 0.04Y0.47). The GEE-model cluster analysis of the lesion-tobackground ratios of APF, AFF, exVol, and exMTT versus the lesionto-background ratios of SUV mean confirmed the significant results after correction for multiple measurements per patient. The lesion-tobackground ratios of the remaining DCE-MRI values (VPF, TPF, UF, and UR) did not show significant correlation with SUV mean .
Fluorodeoxyglucose
The lesion-to-background ratios of SUV mean showed a significantly positive correlation to APF (r = 0.51; P = 0.037; 95% CI, 0.02Y0.80) and AFF (r = 0.68; P = 0.002; 95% CI, 0.28Y0.88) (Fig. 3) . Results of a GEE-model cluster analysis corrected for the multiple measurements per patient confirmed the significance of the correlations. The lesion-to-background ratios of the remaining DCE-MRI values (VPF, TPF, exMTT, exVol, UF, and UR) did not show significant correlation with SUV mean (Table 2) .
DISCUSSION
In the current study, we analyzed the association between DCE-MRI parameters and SUV from PET/CT using different radiotracers.
We showed that the perfusion parameters derived from DCE-MRI and the SUVs derived from PET/CT using 68 Ga-DOTATATE and 18 F-FDG differ significantly between the liver background and the liver metastases. In a further analysis to determine associations between SUV and DCE-MRI, we found a negative correlation between APF and SUV mean derived from 68 Ga-DOTATATE-PET/CT but a positive correlation between APF and SUV mean derived from 18 F-FDG-PET/CT. Interestingly, VPF, TPF, UF, and UR did not show correlations with SUV mean derived from 68 Ga-DOTATATE or 18 F-FDG, although these parameters showed significant differences between metastatic and background liver tissues. These findings might be relevant to the current trend toward hybrid imaging techniques and indicate that the combination of techniques such as MRI/PET may provide additional functional and metabolic information because probably different aspects of liver function are measured using both modalities.
The significant correlations, which we found in our study, can be interpreted using physiologic mechanisms. We showed that both APF (r = j0.54) and AFF (r = j0.39) correlate significantly negative to SUV mean derived from PET/CT with 68 Ga-DOTATATE as tracer and implied that lesions with a relatively high arterial perfusion show a relatively low expression of somatostatin receptors and therefore less specific uptake of 68 Ga-DOTATATE. Kayani et al 24 showed, in a series of 38 consecutive patients, that there is a greater uptake of 68 Ga-DOTATATE in low-grade NEN compared with highgrade NEN (median SUV, 29 vs 4.3, P = 0.0033). Thus, one possible explanation for the negative correlation between APF and SUV mean in our study might be a correlation between DCE-MRI parameters and tumor grading. To our knowledge, there are no reports in the literature on the role of perfusion of neuroendocrine tumor metastases and tumor grading, but similar correlations have been described for renal cell carcinoma. In a study with 21 patients, Palmowski et al 37 reported significantly higher DCE-MRI perfusion values (PG0.05) in high-grade tumors than in intermediate-grade tumors. Unfortunately, our sample size for Ki-67 was not sufficient to prove this trend. Further research is needed to investigate the interdependency between tumor grading and tumor perfusion in NENs.
We also reported that APF (r = 0.51) and AFF (r = 0.68) are positively correlated to the SUV mean derived from PET/CT with 18 F-FDG as tracer and suggest that metabolic activity is linked, either directly or indirectly, to arterial perfusion. Kayani et al 24 were able to show that, conversely to 68 Ga-DOTATATE, there is a higher uptake of 18 F-FDG in high-grade NEN compared with the uptake in low-grade NEN (median SUV, 11.7 vs 2.9). Thus, the positive correlation between DCE-MRI parameters and SUV from 18 F-FDG-PET/CT may also be associated with tumor grading. The association between glucose metabolism and arterial perfusion could also be attributed to biochemical mechanisms. There is evidence that metastatic tissue has impaired oxidative phosphorylation and increased glycolytic rate and lactate production, 38Y41 culminating in increased apoptosis and tumor proliferation. 42 Because anaerobic glycolysis extracts less adenosine triphosphates from glucose molecules than aerobic glycolysis does, there is a higher need for blood supply of glucose in metastatic tissue. This can be achieved either through increased perfusion or through increased extraction fraction of glucose. The latter mechanism could be shown in DCE-MRI in patients with arterial wall in flammation, 43 whereas our results suggest that higher metabolic activity is also associated with increased perfusion. Further studies should aim to explore and quantify the effect of those mechanisms in oncologic patients.
The APF and AFF of NEN metastatic to the liver seem to be surrogate markers for metabolic activity and associated with expression of somatostatin receptors. Therefore, APF and AFF seem relevant to the diagnosis and monitoring of liver metastases. Other DCE-MRI parameters (exMTT and exVol) showed weak correlations to somatostatin receptor status. Still, other DCE-MRI parameters (VPF, TPF, UF, and UR) showed different values for the metastases and the normal liver tissue but did not correlate with SUV, using 18 F-FDG or 68 Ga-DOTATATE, probably related to different physiologic mechanisms measured through PET/CT and DCE-MRI. Therefore, these parameters might have the potential to provide additional information.
Given the current research on therapy-related response assessment in targeted therapies, our results suggest that several DCE-MRI parameters may be potential imaging biomarkers and may provide important information. It should be the aim of future studies to analyze the effect of different treatments on these DCE-MRI parameters and refine which are best suited to monitor treatment response.
We used a dedicated dual-inlet, 2-compartment model with the hepatobiliary contrast agent gadoxetic acid for our DCE-MRI examinations. The technique allowed us to obtain the full range of functional parameters from the time-resolved data acquisition with a detailed morphologic assessment in the hepatobiliary phase in T1w 3D GRE sequences with fat saturation (Fig. 2 ) in 1 comprehensive magnetic resonance examination and only 1 application of a standard dose of contrast agent. Whereas a conventional 1-or 2-compartment model may show inaccurate results because of the physiological properties of gadoxetic acid, the model used in our study was specially designed and validated for this purpose. 11 The low uptake fraction in metastases in the absence of organic anion transporting polypeptide receptors can be explained through interstitial uptake because of the extracellular properties of gadoxetic acid.
The data from our study must be interpreted in the context of the study design. Our patients with NEN metastatic to the liver had long intervals since primary diagnosis and received a variety of Ga-DOTATATE, 68 Ga-DOTA-Tyr(3)-octreotate; APF, arterial plasma flow; CT, computed tomography; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; MTT, mean transit time; n.s., not significant; PET, positron emission tomography; SUV, specific uptake value; TPF, total plasma flow; VPF, venous plasma flow. previous therapies. Embolizing therapies, especially radioembolization and transarterial chemoembolization, might influence DCE-MRI parameters such as the APF and the AFF of the metastases. For PET/ CT examinations, medication with somatostatin analog was not stopped and there was no interval regarding previous octreotid therapies. However, Haug et al 44 showed, in a study of 105 patients, that treatment with somatostatin analog does not affect tumor uptake of 68 Ga-DOTATATE in patients with NEN. Future studies might focus on the association between DCE-MRI parameters and SUV from PET/CT in patients with an initial diagnosis of different types of tumors in the absence of previous therapies. For the definition of the ROIs, we did not have histopathologic correlation. Because NEN may have diffuse liver involvement, even normal-appearing liver tissue may be infiltrated by microscopic tumor invasion. However, we tried to avoid any misclassification by correlation with all available morphologic sequences.
CONCLUSIONS
In conclusion, we were able to show that some DCE-MRI parameters, especially the flow-related, are correlated with SUV from PET/ CT, whereas other parameters correlate poorly or not at all, suggesting that the combination of MR and PET may improve the diagnostic power compared with each technique individually and has the potential to provide additional functional information of the liver.
